Discordant expression of mRNA and protein for urokinase and tissue plasminogen activators (u-PA, t-PA) in endometrial carcinoma

International Journal of Cancer

Volumn 79, Issue 2, 1998, Pages 195-201

  Nordengren, Johanna ^a   Casslén, Bertil ^a   Gustavsson, Barbro ^a   Einarsdottir, Margret ^a   Willén, Roger ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTICLE; AUTORADIOGRAPHY; CANCER STAGING; ENDOMETRIUM CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN DEGRADATION; QUANTITATIVE DIAGNOSIS; RECEPTOR UPREGULATION; RNA TRANSLATION; TRANSCRIPTION REGULATION;

CURETTAGE; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERPLASIA; HYSTERECTOMY; NEOPLASM STAGING; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; TISSUE PLASMINOGEN ACTIVATOR; TRANSCRIPTION, GENETIC; URINARY PLASMINOGEN ACTIVATOR;

EID: 0031919585     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980417)79:2<195::AID-IJC16>3.0.CO;2-9     Document Type: Article

References (29)

1. BOMMER, U.A., LAZARIS-KARATZAS, A., DE BENEDETTI, A., NURNBERG, P., BENNDORF, R., BIELKA H. and SONENBERG, N., Translation regulation of the mammalian growth-related protein P23: involvement of elF-4E. Cell. mol. biol. Res., 40, 633-641 (1994).
2. CAMIOLO, S., MARKUS, G. and PIVER, M., Plasminogen activator content of gynecological tumors and their metastases. Gynecol. Oncol., 26, 364-373 (1987).
3. CAMIOLO, S., SIUTA, M. and MADEJA, J., Improved medium for extraction of plasminogen activator from tissue. Prep. Biochem., 12, 297-305 (1982).
4. CASSLÉN, B. and ÅSTEDT, B., Occurrence of both urokinase and tissue plasminogen activator in the human endometrium. Contraception, 28, 553-564 (1983).
5. CASSLÉN, B., LECANDER, I., BOSSMAR, T. and ÅSTEDT, B., Plasminogen activator and plasminogen activator inhibitors in blood and tumor fluids of patients with ovarian cancer. Europ. J. Cancer, 30A, 1302-1309 (1994).
6. CASSLÉN, B., NORDENGREN, J., GUSTAVSSON, B., NILBERT, M. and LUND, L.R., Progesterone stimulates degradation of urokinase plasminogen activator (u-PA) in endometrial stromal cells by increasing its inhibitor (PAI-1) and surface expression of the u-PA receptor. J. clin. Endocrinol. Metab., 80, 2776-2784 (1995).
7. CASSLÉN, B., THORELL, J. and ÅSTEDT, B. Effect of IUD on urokinase-like immunoreactivity and plasminogen activators in human activators fluid. Contraception, 23, 435-446 (1981).
8. CASSLÉN, B., URANO, S., LECANDER, I. and NY, T., PLASMINOGEN ACTIVATORS IN THE HUMAN ENDOMETRIUM, CELLULAR ORIGIN AND HORMONAL REGULATION. BLOOD, COAGUL. FIBRINOLYSIS., 3, 133-138 (1992).
9. CHU, E. and ALLEGRA, C. J., The role of thymidylate synthase in cellular regulation. Adv. Enzyme Regul., 36, 143-163 (1996).
10. DANØ, K., BEHRENDT, N., BRÜNNER, N., ELLIS, V., PLOUG, M. and PYKE, C., The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis, 8, 189-203 (1994).
11. DUFFY, M. J., O'GRADY, P., DEVANEY, D., O'SIORAIN, L., FENNELLY, J. J. and LIJNEN, H.R., Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res., 48, 1348-1349 (1988).
12. FURNESS, P.N. and LAM, E.W.H., Patterns of basement membrane deposition in benign, premalignant, and malignant endometrium. J. clin. Pathol., 40, 1320-1323 (1987).
13. GLEESON, N., GONSALVES, R., MCGUINNESS, E. and BONNAR, J., Plasminogen activators in endometrial adenocarcinoma. Int. J. Gynecol. Cancer, 1, 223-226 (1991).
14. GOLD, L.I., SAXENA, B., MITTAL, K.R., MARMOR, M., GOSWAMI, S., NACTIGAL, L., KORC, M. and DEMOPOULOS, R.I., Increased expression of transforming growth factor beta isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium. Evidence for paracrine and autocrine action. Cancer Res., 54, 2347-2358 (1994).
15. GRØNDAHL-HANSEN, J., CHRISTENSEN, I.J., ROSENQUIST, C., BRÜNNER, N., MOURIDSEN, H.T., DANØ, K. and BLICHERT-TOFT, M., High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res., 53, 2513-2521 (1993).
16. HART, D. A. and REHEMTULLA, A., Plasminogen activators and their inhibitors: regulators of extracellular proteolysis and cell function. Comp. Biochem. Physiol., 90B, 691-708 (1988).
17. HEWIN, D.H. SAVAGE, P.B., ALDERSON, D. and VIPOND, M.N., Plasminogen activators in oesophageal carcinoma. Brit. J. Surg., 83, 1152-1155 (1996).
18. KAUPPINEN, L., Regulation of the human spermidine synthase mRNA translation by its 5′-untranslated region. FEBS Lett., 365, 61-65 (1995).
19. KLAUSNER, R.D., Regulating the fate of mRNA: the control of cellular iron metabolism. Cell, 72, 19-28 (1993).
20. KOELBL, H., KIRCHHEIMER, J.C., TATRA, G., CHRIST, G. and BINDER, B.R., Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer. Obstet. Gynecol., 72, 252-256 (1988).
21. KURMAN, R.J., Endometrial hyperplasia and its relationship to certain types of carcinoma. In: Surgery in the treatment of gynecologic cancer, p. 11, Antwerp University Press, Antwerp (1988).
22. NIKLASSON, O., SVANBERG, L., THORELL, J., LECANDER, I. and ÅSTEDT, B., Urokinase-like plasminogen activator as a marker of endometrial neoplasia. Cancer, 48, 1484-1486 (1981).
23. NOYES, R.W., HERTIG, A.T. and ROCK, J., Dating the endometrial biopsy. Fertil. Steril., 1, 3-25 (1950).
24. PETTERSSON, F., Annual report on the results of treatment in gynecological cancer, International Federation of Gynecology and Obstetrics, Stockholm (1995).
25. PUJADE-LAURAINE, E., LU, H., MIRSHAHI, S., SORIA, J., SORIA, C., BERNADOU, A., KRUITHOF, E.K.O., LIJNER, H.R. and BURTIN, P., The plasminogen-activation system in ovarian tumors. Int. J. Cancer, 55, 27-31 (1993).
26. RAFFERTY, S.P., DOMACHOWSKE, J.B. and MALECH, H.L., Inhibition of hemoglobin expression by heterologous production of nitric oxide synthase in the K562 erythroleukemic cell line. Blood, 88, 1070-1078 (1996).
27. SAITO, K., NAGASHIMA, M., IWATA, M., HAMADA, H., SUMIYOSHI, K., TAKADA, Y. and TAKADA, A., The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors. Thrombosis Res., 58, 355-366 (1990).
28. SOSZKA, T. and OLSZEWSKI, K., Plasminogen activators and their inhibitors in normal, hyperplastic and carcinomatous human endometrium. Thrombosis Res., 42, 835-846 (1986).
29. SVANBERG, L. and ÅSTEDT, B., Release of plasminogen activator from normal and neoplastic endometrium. Experientia, (Basle) 35, 818-819 (1979).